A Driven and Passionate Team

We are a team dedicated to defeating degeneration. We are passionate about solving problems with rigorous science and translational medicine. We have joined together to discover and develop therapies that will change the lives of patients suffering from neurodegenerative disease.

Join Us
Leadership

Senior Leadership

We have assembled a team with deep scientific, clinical, business and leadership experience and expertise in biotechnology, and specifically in neurodegenerative diseases.
Ryan Watts, Chief Executive Officer
Ryan Watts

Chief Executive Officer

Alex Schuth, Chief Operating and Financial Officer
Alex Schuth

Chief Operating and Financial Officer

Carole Ho, Chief Medical Officer
Carole Ho

Chief Medical Officer

Dana Andersen, Chief Technical and Manufacturing Officer
Dana Andersen

Chief Technical and Manufacturing Officer

Cindy Dunkle, Chief People Officer
Cindy Dunkle

Chief People Officer

Joe Lewcock, Chief Scientific Officer
Joe Lewcock

Chief Scientific Officer

Chris Walsh, Associate General Counsel
Chris Walsh

General Counsel

Katie Peng, Chief Commercial Officer
Katie Peng

Chief Commercial Officer

Peter Chin,  SVP Late Clinical Development & Medical Affairs
Peter Chin

Senior Vice President Late Clinical Development & Medical Affairs

Tony Estrada, Senior Vice President, Discovery Sciences
Tony Estrada

Senior Vice President, Discovery Sciences

Erica Kratz, Vice President, Regulatory
Erica Kratz

Senior Vice President, Regulatory

Tyler Nielsen, Vice President, Corporate Finance
Tyler Nielsen

Senior Vice President, Corporate Finance

Michelle Polowski

Senior Vice President, Development Operations

Matt Troyer, Senior Vice President, Early Clinical
Matt Troyer

Senior Vice President, Early Clinical

Cynthia Wong
Cynthia Wong

Senior Vice President, Portfolio and Program Management

Anthony Delucchi

Vice President, CMC

Wei Dong, Vice President, Drug Safety
Wei Dong

Vice President, Drug Safety

Leah Frautschy, Vice President, Clinical Manufacturing
Leah Frautschy

Vice President, Clinical Manufacturing

Laura Hansen, Vice President, Investor Relations
Laura Hansen

Vice President, Investor Relations

Kirk Henne, Vice President, Translational Pharmacology and Bioanalysis
Kirk Henne

Vice President, Development Sciences

Mark Kafka

Vice President, IP & Transactions, Legal

Fabian Model, Vice President, Biometrics
Fabian Model

Vice President, Biometrics

Michael Ostland

Vice President, Development Europe

Mark Rowen

Vice President, Corporate Development

Board of Directors

Success is accelerated by experience, collaboration and leadership. Denali’s Board of Directors combines expertise across industry, academia, drug development and the investment community, unified by the mission to improve the lives of patients.
Jennifer Cook, Former CEO, Grail
Jennifer Cook

Former CEO, Grail

Jay Flatley, Former CEO, Chairman of Illumina, Inc.
Jay Flatley

Former CEO, Chairman of Illumina, Inc.

Erik Harris, CCO and EVP, Ultragenyx
Erik Harris

CCO and EVP, Ultragenyx

Peter Klein, Former CFO, Microsoft
Peter Klein

Former CFO, Microsoft

Steve Krognes, Former CFO, Denali Therapeutics
Steve Krognes

Former CFO, Denali Therapeutics

Vicki Sato, Chair of Denali Board
Vicki Sato

Chair of Denali Board

David Schenkein, General Partner, GV
David Schenkein

General Partner, GV

Marc Tessier-Lavigne, President, Stanford University
Marc Tessier-Lavigne

Professor, Stanford University

Nancy A. Thornberry, Chair R&D, Former CEO, Kallyope
Nancy A. Thornberry

Chair R&D, Former CEO, Kallyope

Ryan Watts, Chief Executive Officer
Ryan Watts

Chief Executive Officer

Scientific Advisory Board

Denali's Scientific Advisory Board brings experience from both industry and academia to provide insight around biological pathways, therapeutic strategies, and biomarker development.